Off-Patent Biological and Biosimilar Medicines in Belgium: A Market Landscape Analysis.

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

Who cites it

15 citing papers in PubMed.

1. Exploring Stakeholder Perceptions and Experience of Biosimilar Insulin Switching: A Scoping Review.Endocrinology, diabetes & metabolism · 2026
   Article
2. Demand- Versus Supply-Side Policies in Market Penetration of Biosimilars: Which is More Effective?BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy · 2025
   Article
3. Innovative Formulation Strategies for Biosimilars: Trends Focused on Buffer-Free Systems, Safety, Regulatory Alignment, and Intellectual Property Challenges.Pharmaceuticals (Basel, Switzerland) · 2025
   Review
4. Baihu Jia Renshen Decoction Improves Type 1 Diabetic Rats by Modulating Metabolic Profile.International journal of endocrinology · 2025
   Article
5. Charting the Etanercept Journey: Tracing Cost Dynamics in Poland's Off-Patent Market from Reference Drug Rivalry to Biosimilar Monopoly.BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy · 2024
   Article
6. The impact of policy interventions to promote the uptake of biosimilar medicines in Belgium: a nationwide interrupted time series analysis.Health research policy and systems · 2023
   Article
7. Biosimilar competition in European markets of TNF-alpha inhibitors: a comparative analysis of pricing, market share and utilization trends.Frontiers in pharmacology · 2023
   Article
8. How to select a best-value biological medicine? A practical model to support hospital pharmacists.American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists · 2022
   Article
9. Determinants of prescribing decisions for off-patent biological medicines in Belgium: a qualitative study.BMC health services research · 2022
   Review
10. An exploration of biosimilar TNF-alpha inhibitors uptake determinants in hospital environments in Italy, Portugal, and Spain.Frontiers in medicine · 2022
    Article
11. Biosimilar Use and Switching in Belgium: Avenues for Integrated Policymaking.Frontiers in pharmacology · 2022
    Article
12. How to balance valuable innovation with affordable access to medicines in Belgium?Frontiers in pharmacology · 2022
    Article
13. Knowledge and perception of biosimilars in ambulatory care: a survey among Belgian community pharmacists and physicians.Journal of pharmaceutical policy and practice · 2021
    Article
14. The Off-Patent Biological Market in Belgium: Is the Health System Creating a Hurdle to Fair Market Competition?Pharmaceuticals (Basel, Switzerland) · 2021
    Article
15. Perceptions About Biosimilar Medicines Among Belgian Patients in the Ambulatory Care.Frontiers in pharmacology · 2021
    Article

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

Authors and funding

5 authors.

Funding

No grant is acknowledged in the PubMed record.

Abstract

PubMed holds no abstract for this paper.

Indexed as